Registration and Continental Breakfast — Exhibits Open
Welcome and Opening Remarks, Theresa Franco, MSN, RN, Vice President, Cancer Center Clinical Operations, Nebraska Medicine, and Sarah Chart, Senior Director, OptumHealth Education
Building a Better T-Cell: Harnessing the Power of the Immune System to Combat Cancer, Matthew A. Lunning, DO
Researchers have longed to harness the power of a patient’s own immune system to combat his/her disease, but after a variety of promising starts, success has remained elusive. Dr. Lunning will discuss one approach currently being studied using T-cells harvested from the patient, genetically engineered to produce special receptors on their surface — called chimeric antigen receptors (CARs), grown in a laboratory, and then re-infused into the patient. He will identify patients appropriate to receive this type of therapy and describe the challenges in managing treatment-related toxicities.
- State the phases of the process for undergoing CAR T-cell therapy.
- Identify at least one patient population that may benefit from CAR T-cell therapy.
- Describe the potential complications for CAR T-cell therapy and interventions to manage these complications.
Financial Toxicity: Cancer’s Growing Side Effect, Michael Romano, MBA, MSN, BS, RN
Along with fatigue, nausea and pain, oncologists are hearing complaints daily of the life-altering, debilitating financial impact of cancer care. Out-of-pocket expenses related to treatment can influence both quality of life and the quality of care. “Financial toxicity” is the term given to the fiscal side effect of disease and treatment. Mr. Romano will share insights into the extent of this toxicity. He will discuss some of the sources of the overwhelming out-of-pocket expenses faced by patients and their families as they go through treatment, as well as some of the resources health care systems need to have in place to assist patients as they navigate both the physical and financial impact of cancer.
- State at least two reasons cancer-related expenses are rising.
- Identify sources of out-of-pocket expenses experienced by patients being treated for cancer.
Break — Exhibits Open
Haploidentical Stem Cell Transplantation (SCT): Overcoming Limitations of Donor Availability, Vijaya Bhatt, MD
Lack of a suitable matched donor and/or the time needed to find a donor are often the major obstacles to successful treatment with allogeneic SCT. Half-matched related (haploidentical) SCT can be an effective treatment alternative. Dr. Bhatt will review the process of haploidentical transplantation, as well as the benefits and risks involved. He will also discuss methods to address and avoid treatment-related complications leading to optimal patient outcomes.
- Identify appropriate candidates for haploidentical SCT.
- Describe the conditioning regimen for a haploidentical SCT.
- List possible complications associated with haploidentical SCT and explain how those potential complications can be minimized.
Technological Advances in the OR: Robotic Surgery in Oncology, Chad A. LaGrange, MD; James Padussis, MD; and Kerry Rodabaugh, MD
Moderator: Theresa Franco, MSN, RN
The field of robotic surgery has developed rapidly. This form of minimally invasive surgery has many advantages in surgical oncology and has become the standard of treatment for many cancers. This panel of three surgeons will discuss the use of robotic surgery in gynecological oncology, prostate cancer, and gastrointestinal tumors.
- List at least two advantages of robotic surgery for patients.
- Describe two scenarios wherein use of robotic surgery decreased the severity of postoperative morbidity.
- Relate the process for patient selection when determining appropriate candidates for robotic surgery.
Lunch (provided) — Exhibits Open
Current Management of Breast Cancer: A Multidisciplinary Approach, Amber Carter, MS, LCGC; Pavankumar Tandra, MBBS; Debra Spence, RN; Sarah P. Thayer, MD, PhD; Andrew Wahl, MD; and Cheryl Williams, MD
Moderator: Ann Yager, BSRT (R)(T), Oncology Services Director, Nebraska Medicine
Expert treatment of early breast cancer is critical to optimal outcomes. A multidisciplinary team approach is the most effective way to address the important decisions surrounding the diagnosis and treatment of breast cancer. This session will highlight the benefits of a breast cancer team for comprehensive care. Members of such a team will discuss the issues they address with every new breast cancer patient. The role of genetic testing and counseling, surgical and reconstructive options, and adjuvant systemic treatment will be highlighted.
- Describe which patients will benefit most from a multidisciplinary breast cancer team evaluation.
- List key members of an effective multidisciplinary breast cancer team.
- Relate the participation of a breast cancer specialist in the diagnosis and treatment of breast cancer to better patient outcomes.
- Discuss the role of the genetic counselor to support improved patient satisfaction and treatment outcomes in breast cancer.
Break — Exhibits Open
New Directions in Oncology Clinical Trials: Creating the Future in Treatment, Apar Kishor Ganti, MD, and Christopher J. Kratochvil, MD
Scientific advances are now beginning to challenge and change our view of tumors, including the discovery that it may be just as important to know the genetic makeup of a tumor as it is to know its origin when considering treatment approaches. Our expanding understanding of cancer genetics has led to the development of several targeted therapies. Clinical trial design must continue to evolve to take advantage of this ever-growing body of knowledge. Basket trials are one way in which developing science is being integrated into clinical research. As with any other approach to translational medicine, the success of this strategy depends on the rigor of clinical trial design and recruitment. Drs. Ganti and Kratochvil will discuss the collaboration needed to create and support these new trial designs and advance oncology research and knowledge.
- Describe at least one key difference between recruiting a patient to a basket trial versus a more traditional clinical trial.
- Recite one example of the coordination required to create a basket trial.
- List two actions taken by a clinical research department to enhance collaboration and promote oncology research.
Going Beyond the Medicine: A Panel Discussion on Providing Patient Support, Mark H. Fleisher, MD; Nicole Fox, RD, LMNT, CSO; Theresa Franco, MSN, RN; Rebecca Jones, MSPAS, PA-C; and Robyn Zeplin, PT, BS, MPT
Moderator: Sue Wardian Hartung, MSN, RN, OCN, Case Management Nurse, Patient/Family Education for Cancer Care Services, Nebraska Medicine
The cancer experience only begins at diagnosis. Once diagnosed, the disease and its treatment impact the patient and his/her entire family. This impact is physical, emotional and social. Patients come seeking medical care, but their needs will often extend beyond. Comprehensive cancer programs need to include comprehensive patient and family support. This panel, comprised of diverse expertise, will discuss select patient and family support needs and how to recognize those needs; what barriers can prevent patients from accessing support services; and how patients and their families can benefit from support services.
- Describe two examples of services patients undergoing cancer treatment may need outside of direct medical care.
- List two benefits patients and families may realize by accessing select support services.
- Identify one barrier that prevents patients from utilizing select support services while dealing with cancer and cancer treatment.